Published in final edited form as:

Lung. 2009 ; 187(5): 281–289. doi:10.1007/s00408-009-9158-2.

The Effects of Smoking on the Developing Lung: Insights from a Biologic Model for Lung Development, Homeostasis, and Repair

Virender K. Rehan,

Department of Pediatrics, Harbor-UCLA Medical Center, Los Angeles Biomedical Research Institute at Harbor-UCLA, David Geffen School of Medicine at UCLA, 1124 West Carson Street, Torrance, CA 90502, USA

Kamlesh Asotra, and

Tobacco-Related Disease Research Program, Office of the President, University of California, 300 Lakeside Drive, 6th Floor, Oakland, CA 94612, USA

John S. Torday

Department of Obstetrics and Gynecology, Harbor-UCLA, Medical Center, Los Angeles Biomedical Research Institute at Harbor-UCLA, David Geffen School of Medicine at UCLA, 1000 West Carson Street, Torrance, CA 90502, USA

Virender K. Rehan: vrehan@labiomed.org

Abstract

There is extensive epidemiologic and experimental evidence from both animal and human studies that demonstrates detrimental long-term pulmonary outcomes in the offspring of mothers who smoke during pregnancy. However, the molecular mechanisms underlying these associations are not understood. Therefore, it is not surprising that there is no effective intervention to prevent the damaging effects of perinatal smoke exposure. Using a biologic model of lung development, homeostasis, and repair, we have determined that in utero nicotine exposure disrupts specific molecular paracrine communications between epithelium and interstitium that are driven by parathyroid hormone-related protein and peroxisome proliferator-activated receptor (PPAR) γ , resulting in transdifferentiation of lung lipofibroblasts to myofibroblasts, i.e., the conversion of the lipofibroblast phenotype to a cell type that is not conducive to alveolar homeostasis, and is the cellular hallmark of chronic lung disease, including asthma. Furthermore, we have shown that by molecularly targeting PPAR γ expression, nicotine-induced lung injury can not only be significantly averted, it can also be reverted. The concept outlined by us differs from the traditional paradigm of teratogenic and toxicological effects of tobacco smoke that has been proposed in the past. We have argued that since nicotine alters the normal homeostatic epithelial-mesenchymal paracrine signaling in the developing alveolus, rather than causing totally disruptive structural changes, it offers a unique opportunity to prevent, halt, and/or reverse this process through targeted molecular manipulations.

Keywords

Nicotine; Lung development; Tobacco; Smoking; Chronic obstructive pulmonary disease; Chronic lung disease

Introduction

Tobacco smoking and exposure to second-hand smoke, biofuel smoke from cooking stoves, and breathed air pollutants are widely accepted to be causative factors for childhood asthma and chronic obstructive pulmonary disease (COPD) affecting nearly 3 billion people worldwide, predominantly in China, India, and Africa; however, over 15% of COPD occurs in nonsmokers [1]. Chronic obstructive pulmonary disease is irreversible and difficult to treat. Recent studies suggest that exposure of the developing fetal lung in smoking mothers increases the baby's susceptibility to childhood asthma and possibly COPD in later life. Because of the lack of direct experimental evidence, nicotine purportedly does not cause COPD [2]. However, recent data clearly demonstrate that nicotine is directly and specifically responsible for inducing differentiation of developing lung cells from the normal to abnormal phenotype [3–5]. These studies, which focused on understanding the mechanistic effects of nicotine exposure on the developing lung, offer the hope that the compromised lung structure and functions in chronic lung diseases (CLDs) such as asthma and COPD could in the future be reversed to normalcy through pharmacological interventions of specific target molecules.

Barker Hypothesis for CLD

Tager et al. [6] had first shown that side-stream smoke affected fetal lung development in a landmark study of the effects of smoke exposure on neonatal pulmonary function. In a follow-up study it was shown that the levels of the nicotine metabolite cotinine in amniotic fluid correlated positively with the amount of cortisol, known to stimulate lung development [7]. This interrelationship was consistent with the burgeoning concept that antenatal factors could affect normal lung development—infection, hydramnios, hormones, and nutrients. Such thinking expedited Barker's hypothesis that chronic diseases have their origins in utero [8]. The then recent breakthrough success of antenatal glucocorticoids to prevent respiratory distress syndrome further supported the concept that the long-term consequences of intrauterine lung development could be corrected by the judicious use of physiopharmacologic agents [9].

Biologic Model of Lung Development, Homeostasis, and Repair

The molecular mechanisms of lung injuries due to a wide variety of perinatal insults such as barotrauma, oxotrauma, and infection have been recently elucidated by using a cellular/molecular model of normal lung development (Fig. 1) [10–13]. By experimentally determining how nicotine affects the integrated cell-cell signaling mechanism, this review describes the site and gene regulatory networks involved in nicotine's effects on lung structure and function, as a precursor of CLD.

Fostered by the seminal observation that glucocorticoids accelerate alveolar type II (ATII) cell surfactant synthesis by stimulating fibroblast synthesis and secretion of a low-molecular-weight peptide termed fibroblast pneumocyte factor [14], a paracrine growth factor model for the maturation of the pulmonary surfactant system, based on classic mesenchymal-epithelial interactions, has been developed (Fig. 1, steps 1–7). It had previously been shown that mesodermal development was under endocrine control and that early signals emanated from the epithelium to cause differentiation of the immature mesenchyme in the neighboring epithelium [15]. Furthermore, Brody's group originally showed that the developing lung fibroblast acquired an adipocyte-like phenotype termed the "lipid-laden fibroblast," leaving open the question as to whether these cells might be a source of lipid substrate for surfactant synthesis by the ATII cell [16]. Extending these observations, it was discovered that coculture of lipid-laden fibroblasts with type II cells resulted in the trafficking of the lipid from the fibroblast to the type II cell and its highly enriched incorporation into surfactant phospholipids, particularly when treated with glucocorticoids, suggesting a specific regulated mechanism for neutral lipid trafficking [17]. Interestingly, the fibroblasts take up neutral lipid but do not release

it unless they are in the presence of type II cells; conversely, the type II cells are unable to take up neutral lipid. These observations led to the discovery that type II cell secretion of prostaglandin E₂ caused the release of neutral lipid from the fibroblasts, but the nature of the lipid uptake mechanism by the type II cells remained unknown [18]. However, it had been shown that the synthesis of pulmonary surfactant was an “on-demand” system in which increased respiration resulted in increased surfactant production [19–21], suggesting a stretch-sensitive signal from the type II cell. This led to studying the role of parathyroid hormone-related protein (PTHrP) in lung development because (1) it was expressed in the embryonic endoderm [22]; (2) its receptor was present on the adipoepithelial mesoderm [23]; (3) it had been shown to be a stretch-regulated gene in the urinary bladder [24] and uterus [25], and distension of the lung was known to be of physiologic importance in normal lung development [26]; and (4) knockout of PTHrP caused stage-specific inhibition of fetal lung alveolarization in the transition from the pseudoglandular to the canalicular stage [27].

Early functional studies of PTHrP showed that it was a paracrine factor that stimulated surfactant phospholipid synthesis [28] and that it was stretch-regulated [29]. It was subsequently discovered that PTHrP stimulated neutral lipid uptake by the developing lung fibroblast (~lipofibroblasts) [30] by upregulating adipocyte differentiation-related protein (ADRP), a molecule shown to be necessary for lipid uptake and storage [31], which was subsequently found to be necessary for the transit of neutral lipid from the lipofibroblast to the ATII cell for surfactant phospholipid synthesis [32]. However, how PTHrP regulated lung surfactant via a lipofibroblast paracrine factor was still not known. Since lipofibroblasts are similar to adipocytes, it was hypothesized that lipofibroblasts would, like fat cells, express leptin, which would then bind to the type II cell and stimulate surfactant synthesis. Indeed, lipofibroblasts were shown to express leptin during rat lung development just prior to the onset of surfactant synthesis by type II cells [33]. Importantly, type II cells express the leptin receptor, thus providing a ligand-receptor signaling pathway between the lipofibroblast and the type II cell [34]. PTHrP was shown to stimulate leptin expression by fetal lung fibroblasts, thus providing a complete growth factor-mediated paracrine loop for the synthesis of pulmonary surfactant, as predicted by the PTHrP-based model of lung development [34].

Because the major effectors of normal lung development, such as barotrauma, oxotrauma, and infection, cause alveolar type II cell injury and damage, the effects of PTHrP deprivation on the lipofibroblast phenotype was next examined. It was discovered that in the absence of PTHrP, the lipofibroblast transdifferentiates to a myofibroblast, the cell-type that characterizes lung fibrosis [35]. Furthermore, myofibroblasts cannot sustain type II cell growth and differentiation whereas the lipofibroblast can, demonstrating the functional significance of these two fibroblast phenotypes for lung development. Importantly, when myofibroblasts are treated with a PPAR γ agonist they revert back to the lipofibroblast phenotype, including their ability to promote type II cell growth and differentiation [35].

Effects of Nicotine on the Developing Lung

Tobacco smoke exposure of the developing infant in a pregnant woman who smokes begins in utero and continues throughout the fulminate period of lung development (up to age 8 years). There are well-documented short- and long-term effects of smoke exposure on lung physiology and pathophysiology that have life-long consequences. There is strong epidemiologic and experimental evidence that fetal exposure to maternal smoking during gestation results in detrimental long-term effects on lung growth and function (Table 1) [36–55]. Significant suppression of alveolarization, functional residual capacity, and tidal flow volume has been demonstrated in the offspring of women who smoked during pregnancy. It is important to emphasize that the main effects of in utero nicotine exposure on lung growth and differentiation are likely the result of specific alterations in late fetal lung development rather than its

teratogenic or toxicological effects. These alterations in specific developmental and maturational programs may be subtle and thereby may explain significant long-term adverse pulmonary outcome with only minor immediate effects. The premise, therefore, is that nicotine exposure modifies physiologic development, i.e., its effects are part of the continuum of normal lung development, and therefore should be viewed as such and not as the traditional paradigm of teratogenic and toxicological effects of tobacco smoke. If this premise is valid, it allows for possible corrective treatment based on developmental and physiologic principles, whereas toxic, teratogenic effects would be less likely to be reversed since they lack an integrated, physiologic process. The underlying mechanisms and effector molecules involved in this process are not completely understood. However, it has been shown convincingly that in utero nicotine exposure disrupts specific molecular paracrine communications between epithelium and interstitium that are driven by PTHrP and PPAR γ (see above), resulting in transdifferentiation of lung lipofibroblasts to myofibroblasts [3–5], i.e., the conversion of the lipofibroblast phenotype to a cell type that is not conducive to alveolar homeostasis and is the cellular hallmark of CLD, including asthma [56]. We had previously clearly demonstrated that PPAR γ expression is a key determinant of the lipofibroblast phenotype and that by molecularly targeting PPAR γ expression, nicotine-induced lung injury can be significantly averted under both in vitro and in vivo conditions [3–5].

Evidence that Nicotine is the Main Agent that Causes Lung Injury in the Developing Fetus of the Pregnant Smoker

Although some of the effects of maternal smoking on the developing lung have been suggested to be stress-induced, the direct effects of maternal smoke on prenatal lung growth are constrained only by those components of maternal smoke that are transferred across the placenta. Although there are many agents in smoke that may be detrimental to the developing lung, there is evidence to support the idea that nicotine directly alters fetal lung development. Nicotine crosses the human placenta with minimal biotransformation to its metabolite cotinine [57]. It is accumulated in fetal blood, maternal milk, and amniotic fluid despite increased nicotine clearance during pregnancy, resulting in the fetus being exposed to even higher levels than those of the smoking mother [58–60]. Nicotine accumulates in several fetal tissues, including the respiratory tract [61], thereby suggesting nicotine as the likely agent that alters lung development in the fetus of the pregnant smoker. This is also supported by in vitro work done by others and by our data that show direct effects of nicotine on pulmonary ATII cells and fibroblasts isolated from the developing lung [61–63].

Level of Nicotine Exposure in Smokers

Although the dose of in vivo nicotine used in various studies to determine its systemic effects has ranged from 0.25 to 6 mg/kg, the range of nicotine intake in habitual smokers in one study was 0.16 to 1.8 mg/kg body weight [64,65]. Because of this and the accelerated nicotine clearance during pregnancy in animal studies, the standard dose of nicotine used to mimic nicotine exposure in human smokers is 0.5 to 2.0 mg/kg per day, which is equivalent to an exposure to light (0.5 pack day⁻¹) to moderately heavy (2 pack day⁻¹) smoke exposure [64–68]. Typically, nicotine patches and gum deliver half to one quarter the nicotine dose of cigarette smoking, respectively [66].

Relationship of Maternal Smoking to Prenatal and Postnatal Lung Growth

There is extensive evidence from both animal and human studies of the reduction in both prenatal and postnatal lung growth in the offspring of mothers who smoke during pregnancy [6,37–43,67–77]. Arrested lung growth and lung hypoplasia have been reported after prenatal nicotine exposure in animal models [36,39–41,61,65,69–74,77]. The hypoplastic fetal lungs

of in utero smoke-exposed rat fetuses contain fewer and larger saccules that are more compliant and have reduced parenchymal tissue, septal crests, and markedly reduced surface area available for gas exchange [39]. It is important to realize that the mechanisms for prenatal and postnatal lung effects are likely to be different, and evidence suggests that prenatal exposure to tobacco smoke components may play a much greater role in altered lung function than postnatal or childhood exposures [75]. The pulmonary changes appear to occur early in pregnancy because respiratory function in premature infants of smoking mothers is significantly reduced compared to premature infants of nonsmokers [76].

Specific Cellular and Molecular Effects of Nicotine on the Developing Lung

Despite decades of research, specific cellular and molecular effects through which in utero nicotine exposure affects lung growth, development, and function remain incompletely understood [69]. Various investigators have pursued nicotine's effects on individual lung cell types or specific molecular pathways, but none of the models proposed so far explains the morphologic, molecular, and functional changes seen following in utero nicotine exposure completely. Alveolar type II cell hyperplasia and abnormal differentiation have been reported in rat and fetal monkey models of in utero nicotine exposure [61,67,74]. In the fetal monkey model, upregulation of α -7 nicotinic acetylcholine receptors in the lung and an increase in collagen and elastin deposition in airways were observed [67]. In the rat model, it was recently demonstrated that in utero nicotine exposure significantly stimulates ATII cell proliferation, differentiation, and metabolism [4]. Furthermore, it was shown that the nicotine-mediated stimulation of surfactant synthesis was by its direct effect on ATII cells, whereas ATII cell proliferation and metabolism were mediated via its paracrine effects on the alveolar epithelial fibroblasts, permanently altering the "developmental program" of the developing lung. Nicotine's effects on lung fibroblasts have also been explored in rat and monkey models of perinatal nicotine exposure [67,71–73]. Under in vitro conditions it was shown that nicotine exposure disrupts epithelial-mesenchymal interactions and causes lipofibroblast-to-myofibroblast transdifferentiation [3,5]. More importantly, in these studies, targeting specific alveolar interstitial fibroblast molecular intermediates effectively blocked nicotine's adverse effects on the developing lung. In addition to nicotine's effects on ATII cells and fibroblasts, its effects on pulmonary neuroendocrine cells via the activation of the paracrine serotonin pathway have also been described [78]. Therefore, prenatal nicotine exposure seems to alter lung development through multiple pathways, but a clear understanding of the underlying mechanisms involved and the mechanistic link between perinatal nicotine exposure and altered pulmonary structure and function are still not completely understood. Consequently, it is not surprising that there is no effective intervention to prevent the damaging effects of in utero nicotine exposure, though some strategies such as vitamin C and copper supplementation have been suggested as attractive options [70,73]. However, the safety of these interventions is not established, the mechanisms underlying possible beneficial effects remain poorly understood, and the protection afforded is only partial and inconsistent. Given that despite enthusiastic antismoking campaigns, 12% of U.S. women still smoke during pregnancy, resulting in the birth of 450,000 smoke-exposed infants in 2002 [79]. Effective and safe interventions that are based upon a sound understanding of the molecular mechanisms involved in nicotine-induced lung injury are needed. Our studies have begun to precisely address these mechanisms and have already provided valuable and unique insights [3–5,80,81].

Barring some of the work from our group, reviewed above, no other studies seem to account for all of the pulmonary abnormalities seen following in utero nicotine exposure. For example, the paradox of advanced pulmonary maturity at birth and ultimate poor long-term pulmonary outcome is not explained by any of the previously proposed mechanisms. Since nicotine disrupts the specific homeostatic epithelial-mesenchymal pulmonary communications, inhibiting PTHrP/PPAR γ signaling and stimulating Wnt signaling, culminating in

lipofibroblast-to-myofibroblast transdifferentiation, this could potentially explain all of the known long-term pulmonary effects following in utero nicotine exposure, including the increased predisposition to childhood asthma [3–5,80,81]. Previous observations by others that there is decreased cellular lipid content and increased mitotic activity of fetal lung tissue in nicotine-exposed rat pups versus control pups are also consistent with the lipofibroblast-to-myofibroblast transdifferentiation following in utero nicotine exposure [35,74]. The advanced pulmonary maturity at birth is explained by the direct pharmacologic effects of nicotine on ATII cells that lead to their pseudomaturization, which because of the breakdown of the underlying homeostatic epithelial-mesenchymal communications, ultimately fails, explaining both failed alveolarization and increased predisposition to asthma later in life in in utero smoke-exposed infants. Furthermore, the molecular basis for the increased generation of lung myofibroblasts, the key players in the pathophysiology of asthma and which contribute not only to tissue remodeling but also to airway inflammation, is clearly explained by the downregulation of PTHrP/PPAR γ signaling and by the upregulation of Wnt signaling in nicotine-exposed lungs. Therefore, in addition to the abnormalities in lung structure, the increased generation of myofibroblasts in nicotine-exposed lungs explains the adverse long-term pulmonary outcomes in infants exposed to smoke during development [6,37,41,75,82,83]. This paradigm provides a plausible and powerful unifying explanation for all of the nicotine-associated pulmonary morphometric, histologic, molecular, and functional abnormalities, setting the stage for not only effectively blocking but also possibly reversing these alterations by specific molecular targeting of lipofibroblast PTHrP/PPAR γ and Wnt signaling intermediates (Table 2) [5].

In summary, this review provides evidence for nicotine-induced lipofibroblast-to-myofibroblast transdifferentiation; alterations in ATII cell proliferation, differentiation, and metabolism; deleterious effects on pulmonary function; downregulation of the lipofibroblast PPAR γ signaling and activation of Wnt signaling; and effective prevention of nicotine-induced effects on lipofibroblasts, ATII cells, and pulmonary function by targeting specific molecular intermediates of the PPAR γ signaling pathway [3–5,80,81]. These findings, for the first time, provide a unifying mechanistic basis for various pulmonary morphologic and molecular features that are known to follow in utero nicotine exposure. Specifically, the downregulation of PPAR γ signaling and the upregulation of Wnt signaling, resulting in lipofibroblast-to-myofibroblast transdifferentiation, are likely to be central molecular events in this process. The lipofibroblast-to-myofibroblast transdifferentiation, along with abnormal ATII cell proliferation and differentiation, explains the paradox of advanced pulmonary maturity at birth and increased predisposition to CLD in in utero nicotine-exposed infants.

Antenatal Steroid Administration for RDS as a Precedent for PPAR γ Agonist Administration for CLD

Glucocorticoids have been used effectively to reduce the risk of respiratory distress syndrome (RDS) for over 30 years [9,84]. This breakthrough in treating the fetus as a patient was preceded by extensive studies of the effects and mechanism of glucocorticoid action on normal lung development. The first double-blind clinical trial of glucocorticoid effects on lung development published in 1972 showed that it was safe and effective in lowering the incidence of RDS. However, there were aspects of the treatment that were of concern, namely, the lack of a statistically significant effect in males. A subsequent series of studies revealed that the male hormone inhibited the effect of glucocorticoids on the differentiation of the lung fibroblasts [85–87]. More recent studies of the mechanism of androgen action have shown that androgens stimulate the Wnt pathway by increasing β -catenin expression [88]; similar results have been obtained with nicotine [80,81], suggesting a common pathway for androgen and nicotine blocking glucocorticoid-induced fetal lung development. However, PPAR γ agonists can effectively block the inhibitory effect of nicotine on fetal lung fibroblast differentiation [3–

5]. Bearing in mind that antenatal glucocorticoids have a less than optimal effect on fetal lung development, testing the effects of antenatal and postnatal PPAR γ agonists on this process is worthwhile and in progress [89]. Promising preliminary data show that PPAR γ agonists accelerate lung development and that its effect is non-gender-dependent, calling for a clinical trial of this therapy in the near future.

Conclusion

Given that more than 400,000 infants are exposed to maternal smoke per annum in the US alone, maternal smoking is a huge worldwide public health problem. And given that the cost of advertising for smoking increased by over one billion dollars from 2001 to 2002, it is unlikely that the problem of smoking during pregnancy will go away any time soon. Therefore, the organ-specific mechanisms for the harmful effects of in utero smoke exposure need to be thoroughly understood before there is any real chance of its prevention. For example, with the approaches adopted so far, the mechanism for the 40% increase in clinically impaired lung function of the in utero smoke-exposed infants on follow-up is not known. As reviewed here, in utero nicotine exposure disrupts the homeostatic alveolar interaction between the alveolar lung fibroblast PPAR γ and Wnt signaling pathways, offering a unique mechanistic perspective and an exceptional translational opportunity. This concept differs from the traditional paradigm of the teratogenic and toxicological effects of tobacco smoke that has been proposed to underlie nicotine-related pulmonary damage in the past. Since nicotine seems to alter the normal homeostatic epithelial-mesenchymal paracrine signaling in the developing alveolus, rather than causing totally disruptive structural changes, there is a distinct opportunity to prevent, halt, and/or reverse this process through targeted molecular manipulations, e.g., PPAR γ administration. And because of the relatively recent exposure of humans to cigarette smoke, it is likely that elucidation of the deleterious effects of nicotine on the lung will help in understanding other chronic lung diseases due to failed cell-cell signaling as well.

Acknowledgments

This study was supported by research grants from the National Institutes of Health (HL075405, HL55268, HD51857) and the California Tobacco-Related Disease Research Program (14RT-0073, 15IT-0250 and 17RT-0170) to VKR and JST, and to KA from the National Institutes of Health (R13 ES016516), Flight Attendant Medical Research Institute, Society for Free Radical Research International, and the California Oxygen Club.

References

1. Editorial. Beyond the lungs—a new view of COPD. *Lancet* 2007;370:713. [PubMed: 17765500]
2. Britton J, Edwards R. Tobacco smoking, harm reduction, and nicotine product regulation. *Lancet* 2008;371:443–445.
3. Rehan VK, Wang Y, Sugano S, Romero S, Chen X, Santos J, Khazanchi A, Torday JS. Mechanism of nicotine-induced pulmonary fibroblast transdifferentiation. *Am J Physiol Lung Cell Mol Physiol* 2005;289:L667–L676. [PubMed: 15951329]
4. Rehan VK, Wang Y, Sugano S, Santos J, Patel S, Sakurai R, Boros LG, Lee WP, Torday JS. In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism. *Am J Physiol Lung Cell Mol Physiol* 2007;292:L323–L333. [PubMed: 17215434]
5. Rehan VK, Sakurai R, Wang Y, Huynh K, Torday JS. Reversal of nicotine-induced alveolar lipofibroblast-to-myofibroblast transdifferentiation by stimulants of parathyroid hormone-related protein signaling. *Lung* 2007;185:151–159. [PubMed: 17401602]
6. Tager IB, Weiss ST, Muñoz A, Rosner B, Speizer FE. Longitudinal study of the effects of maternal smoking on pulmonary function in children. *N Engl J Med* 1983;309:699–703. [PubMed: 6888441]
7. Lieberman E, Torday J, Barbieri R, Cohen A, Van Vunakis H, Weiss ST. Association of intrauterine cigarette smoke exposure with indices of fetal lung maturation. *Obstet Gynecol* 1992;79:564–570. [PubMed: 1553178]

8. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ* 1989;298:564–567. [PubMed: 2495113]
9. Liggins GC, Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics* 1972;50:515–525. [PubMed: 4561295]
10. Sanchez-Esteban J, Tsai SW, Sang J, Qin J, Torday JS, Rubin LP. Effects of mechanical forces on lung-specific gene expression. *Am J Med Sci* 1998;316:200–204. [PubMed: 9749563]
11. Rehan VK, Wang Y, Patel S, Santos J, Torday JS. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo. *Pediatr Pulmonol* 2006;41:558–569. [PubMed: 16617452]
12. Dasgupta C, Wang Y, Sakurai R, Torday JS, Rehan VK. Hyperoxia-induced neonatal lung injury involves activation of TGF- β and Wnt signaling: protection by rosiglitazone. *Am J Physiol Lung Cell Mol Physiol* 2009;296:L1031–L1041. [PubMed: 19304912]
13. Rehan VK, Dargan-Batra SK, Wang Y, Cerny L, Sakurai R, Santos J, Beloosesky R, Gayle D, Torday JS. A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L182–L190. [PubMed: 17435078]
14. Smith BT. Lung maturation in the fetal rat: acceleration by injection of fibroblast-pneumonocyte factor. *Science* 1979;204:1094–1095. [PubMed: 582216]
15. Heuberger B, Fitzka I, Wasner G, Kratochwil K. Induction of androgen receptor formation by epithelium-mesenchyme interaction in embryonic mouse mammary gland. *Proc Natl Acad Sci USA* 1982;79:2957–2961. [PubMed: 6953441]
16. Vaccaro C, Brody JS. Ultrastructure of developing alveoli. I. The role of the interstitial fibroblast. *Anat Rec* 1978;192:467–479. [PubMed: 736269]
17. Torday J, Hua J, Slavin R. Metabolism and fate of neutral lipids of fetal lung fibroblast origin. *Biochim Biophys Acta* 1995;1254:198–206. [PubMed: 7827125]
18. Torday JS, Sun H, Qin J. Prostaglandin E2 integrates the effects of fluid distension and glucocorticoid on lung maturation. *Am J Physiol* 1998;274:L106–L111. [PubMed: 9458807]
19. Faridy EE, Permutt S, Riley RL. Effect of ventilation on surface forces in excised dogs' lungs. *J Appl Physiol* 1966;21:1453–1462. [PubMed: 5923215]
20. Wyszogrodski I, Kyei-Aboagye K, Taeusch HW Jr, Avery ME. Surfactant inactivation by hyperventilation: conservation by end-expiratory pressure. *J Appl Physiol* 1975;38:461–466. [PubMed: 1097385]
21. Oyarzun MJ, Clements JA, Baritussio A. Ventilation enhances pulmonary alveolar clearance of radioactive dipalmitoyl phosphatidylcholine in liposomes. *Am Rev Respir Dis* 1980;121:709–721. [PubMed: 6892983]
22. Hastings RH, Duong H, Burton DW, Deftos LJ. Alveolar epithelial cells express and secrete parathyroid hormone-related protein. *Am J Respir Cell Mol Biol* 1994;11:701–706. [PubMed: 7946399]
23. Lee K, Deeds JD, Segre GV. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. *Endocrinology* 1995;136:453–463. [PubMed: 7835276]
24. Yamamoto M, Harm SC, Grasser WA, Thiede MA. Parathyroid hormone-related protein in the rat urinary bladder: a smooth muscle relaxant produced locally in response to mechanical stretch. *Proc Natl Acad Sci USA* 1992;89:5326–5330. [PubMed: 1376916]
25. Daifotis AG, Weir EC, Dreyer BE, Broadus AE. Stretch-induced parathyroid hormone-related peptide gene expression in the rat uterus. *J Biol Chem* 1992;267:23455–23458. [PubMed: 1385422]
26. Alcorn D, Adamson TM, Lambert TF, Maloney JE, Ritchie BC, Robinson PM. Morphological effects of chronic tracheal ligation and drainage in the fetal lamb lung. *J Anat* 1977;123:649–660. [PubMed: 885780]
27. Rubin LP, Kovacs CS, De Paepe ME, Tsai SW, Torday JS, Kronenberg HM. Arrested pulmonary alveolar cytodifferentiation and defective surfactant synthesis in mice missing the gene for parathyroid hormone-related protein. *Dev Dyn* 2004;230:278–289. [PubMed: 15162506]

28. Rubin LP, Kifor O, Hua J, Brown EM, Torday JS. Parathyroid hormone (PTH) and PTH-related protein stimulate surfactant phospholipid synthesis in rat fetal lung, apparently by a mesenchymal-epithelial mechanism. *Biochim Biophys Acta* 1994;1223:91–100. [PubMed: 8061059]
29. Torday JS, Sanchez-Esteban J, Rubin LP. Paracrine mediators of mechanotransduction in lung development. *Am J Med Sci* 1998;316:205–208. [PubMed: 9749564]
30. McGowan SE, Torday JS. The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. *Annu Rev Physiol* 1997;59:43–62. [PubMed: 9074756]
31. Gao J, Serrero G. Adipose differentiation related protein (ADRP) expressed in transfected COS-7 cells selectively stimulates long chain fatty acid uptake. *J Biol Chem* 1999;274:16825–16830. [PubMed: 10358026]
32. Schultz CJ, Torres E, Londos C, Torday JS. Role of adipocyte differentiation-related protein in surfactant phospholipid synthesis by type II cells. *Am J Physiol Lung Cell Mol Physiol* 2002;283:L288–L296. [PubMed: 12114189]
33. Torday JS, Sun H, Wang L, Torres E, Sunday ME, Rubin LP. Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation. *Am J Physiol Lung Cell Mol Physiol* 2002;282:L405–L410. [PubMed: 11839533]
34. Torday JS, Rehan VK. Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin. *Am J Physiol Lung Cell Mol Physiol* 2002;283:L130–L135. [PubMed: 12060569]
35. Torday JS, Torres E, Rehan VK. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation and repair in vitro. *Pediatr Pathol Mol Med* 2003;22:189–207. [PubMed: 12746170]
36. Blacquire MJ, Timens W, Melgert BN, Geerlings M, Postma DS, Hylkema MN. Maternal smoking during pregnancy induces airway remodeling in mice offspring. *Eur Respir J* 2009;33:1133–1140. [PubMed: 19129273]
37. Moshhammer H, Hoek G, Luttmann-Gibson H, Neuberger MA. Parental smoking and lung function in children: an international study. *Am J Respir Crit Care Med* 2006;173:1255–1263. [PubMed: 16484675]
38. Hofhuis W, de Jongste JC, Merkus PJ. Adverse health effects of prenatal and postnatal tobacco smoke exposure on children. *Arch Dis Child* 2003;88:1086–1090. [PubMed: 14670776]
39. Collins MH, Moessinger AC, Kleinerman J. Fetal lung hypoplasia associated with maternal smoking: a morphometric analysis. *Pediatr Res* 1985;19:408–412. [PubMed: 4000765]
40. Bassi JA, Rosso P, Moessinger AC, Blanc WA, James LS. Fetal lung growth retardation due to maternal tobacco smoke exposure in the rat. *Pediatr Res* 1984;18:127–130. [PubMed: 6199726]
41. Maritz GS, Dennis H. Maternal nicotine exposure during gestation and lactation interferes with alveolar development in the neonatal lung. *Reprod Fertil Dev* 1998;10:255–261. [PubMed: 11596872]
42. Cunningham J, Dockery DW, Speizer FE. Maternal smoking during pregnancy as a predictor of lung function in children. *Am J Epidemiol* 1994;139:1139–1152. [PubMed: 8209873]
43. Hanrahan JP, Tager IB, Segal MR. The effect of maternal smoking during pregnancy on early infant lung function. *Am Rev Respir Dis* 1992;145:1129–1135. [PubMed: 1586058]
44. Strachan DP, Cook DG. Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood. *Thorax* 1997;52:905–914. [PubMed: 9404380]
45. DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. *Pediatrics* 2004;113:1007–1015. [PubMed: 15060193]
46. Haberg SE, Stigum H, Nystad W, Nafstad P. Effects of pre- and postnatal exposure to parental smoking on early childhood respiratory health. *Am J Epidemiol* 2007;166:679–686. [PubMed: 17625224]
47. Shah T, Sullivan K, Carter J. Sudden infant death syndrome and reported maternal smoking during pregnancy. *Am J Public Health* 2006;96:1757–1759. [PubMed: 17008569]
48. Eugenin J, Otrola M, Bravo E, Coddou C, Cerpa V, Reyes-Parada M, Llona I, von Bernhardt R. Prenatal to early postnatal nicotine exposure impairs central chemoreception and modifies breathing pattern in mouse neonates: a probable link to sudden infant death syndrome. *J Neurosci* 2008;28:13907–13917. [PubMed: 19091979]

49. Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PN. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. *Lancet* 1996;348:1060–1064. [PubMed: 8874457]
50. Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Vora H, Rappaport EB, Avol E, Peters JM. Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. *Thorax* 2000;55:271–276. [PubMed: 10722765]
51. von Mutius E. Environmental factors influencing the development and progression of pediatric asthma. *J Allergy Clin Immunol* 2002;109:5525–5532.
52. Strachan DP, Cook DG. Health effects of passive smoking. 1. Parental smoking and childhood asthma: longitudinal and case control studies. *Thorax* 1998;53:204–212. [PubMed: 9659358]
53. Rennard SI, Togo S, Holz O. Cigarette smoke inhibits alveolar repair. *Proc Am Thorac Soc* 2006;3:703–708. [PubMed: 17065377]
54. Coultas DB. Health effects of passive smoking. 8. passive smoking and risk of adult asthma and COPD. *Thorax* 1998;53:381–387. [PubMed: 9708231]
55. Le Souef PN. Pediatric origins of adult lung diseases. 4. Tobacco related lung diseases begin in childhood. *Thorax* 2000;55:1063–1067. [PubMed: 11083894]
56. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. *Am J Pathol* 2007;170:1807–1816. [PubMed: 17525249]
57. Luck W, Nau H. Nicotine and cotinine concentrations in serum and milk of nursing smokers. *Br J Clin Pharmacol* 1984;18:9–15. [PubMed: 6743492]
58. Dempsey D, Jacob P 3rd, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. *J Pharmacol Exp Ther* 2002;301:594–598. [PubMed: 11961061]
59. Luck W, Nau H, Hansen R, Steldinger R. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. *Dev Pharmacol Ther* 1985;8:384–395. [PubMed: 4075937]
60. Szuts T, Olsson S, Lindquist NG, Ullberg S, Pilotti A, Enzell C. Long-term fate of [¹⁴C]nicotine in the mouse: retention in the bronchi, melanin-containing tissues and urinary bladder wall. *Toxicology* 1978;10:207–220. [PubMed: 705796]
61. Maritz GS, Thomas RA. Maternal nicotine exposure: response of type II pneumocytes of neonatal rat pups. *Cell Biol Int* 1995;19:323–331. [PubMed: 7613520]
62. Roman J, Ritzenthaler JD, Gil Costa A, Rivera HN, Roser-Page S. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. *FASEB J* 2004;18:1436–1438. [PubMed: 15247149]
63. Wuenschell CW, Zhao J, Tefft JD, Warburton D. Nicotine stimulates branching and expression of SP-A and SP-C mRNA in embryonic mouse lung culture. *Am J Physiol* 1998;278:L165–L170. [PubMed: 9458815]
64. Matta SG, Balfour DJ, Benowitz NL, Boyd RT. Guidelines on nicotine dose selection for in vivo research. *Psychopharmacology (Berl)* 2007;190:269–319. [PubMed: 16896961]
65. Maritz GS, Woolward KM. Effect of maternal nicotine exposure on neonatal lung elastic tissue and possible consequences. *S Afr Med J* 1992;81:517–519. [PubMed: 1585224]
66. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. *N Eng J Med* 1988;319:1318–1330.
67. Sekhon HS, Keller JA, Proskocil BJ, Martin EL, Spindel ER. Maternal nicotine exposure upregulates collagen gene expression in fetal monkey lung: association with $\alpha 7$ nicotinic acetylcholine receptors. *Am J Respir Cell Mol Biol* 2002;26:31–41. [PubMed: 11751201]
68. Chen CM, Wang LF, Yeh TF. Effects of maternal nicotine exposure on lung surfactant system in rats. *Pediatr Pulmon* 2005;39:97–102.
69. Pierce RA, Nguyen NM. Prenatal nicotine exposure and abnormal lung function. *Am J Respir Cell Mol Biol* 2002;26:1013.
70. Proskocil BJ, Sekhon HS, Clark JA, Lupo SL. Vitamin C prevents the effects of prenatal nicotine on pulmonary function in newborn monkeys. *Am J Respir Crit Care Med* 2005;171:1032–1039. [PubMed: 15709053]

71. Sekhon HS, Jia Y, Raab R, Kuryatov A. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. *J Clin Invest* 1999;103:637–647. [PubMed: 10074480]
72. Sekhon HS, Keller JA, Benowitz NL, Spindel ER. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. *Am J Respir Crit Care Med* 2001;164:989–994. [PubMed: 11587984]
73. Maritz GS, Matthews HL, Aalbers J. Maternal copper supplementation protects the neonatal rat lung against adverse effects of maternal nicotine exposure. *Reprod Fertil Dev* 2000;12:97–103. [PubMed: 11194564]
74. Kordom C, Maritz GS, De Kock M. Maternal nicotine exposure during pregnancy and lactation: I. Effect on glycolysis in the lungs of the offspring. *Exp Lung Res* 2003;29:29–89. [PubMed: 12652814]
75. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. *Am J Respir Crit Care Med* 1995;152:977–983. [PubMed: 7663813]
76. Hoo AF, Henschen M, Dezateux C, Costeloe K, Stocks J. Respiratory function among preterm infants whose mothers smoked during pregnancy. *Am J Respir Crit Care Med* 1998;158:700–705. [PubMed: 9730993]
77. Sandberg K, Poole SD, Hamdan A, Arbogast P, Sundell HW. Altered lung development after prenatal nicotine exposure in young lambs. *Pediatr Res* 2004;56:432–439. [PubMed: 15240863]
78. Van Lommel A. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development. *Paediatr Respir Rev* 2001;2:171–176. [PubMed: 12531066]
79. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2002. *Natl Vital Stat Rep* 2003;52:1–113. [PubMed: 14717305]
80. Wang Y, Santos J, Sakurai R, O’Roark E, Kenyon N, Torday JS, Rehan VK. Prevention of perinatal nicotine exposure-induced alterations in pulmonary function by Peroxisome Proliferator Activated Receptor gamma (PPAR γ) agonists. *J Invest Med* 2007;56:A124.
81. Cerny LM, Sakurai R, Wang Y, Guo P, Torday JS, Rehan VK. Mechanism of nicotine-induced up-regulation of wingless/int (Wnt) signaling in human alveolar interstitial fibroblasts. *J Invest Med* 2008;56:A287.
82. Mannino DM, Moorman JE, Kingsley B, Rose D, Repace J. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Pediatr Adolesc Med* 2001;155:36–41. [PubMed: 11177060]
83. Landau LI. Tobacco smoke exposure and tracking of lung function into adult life. *Paediatr Respir Rev* 2008;9:39–43. [PubMed: 18280978]
84. National Institutes of Health. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994;12:1–24.
85. Nielsen HC. Testosterone regulation of sex differences in fetal lung development. *Proc Soc Exp Biol Med* 1992;199:446–452. [PubMed: 1549623]
86. Rodriguez A, Viscardi RM, Torday JS. Fetal androgen exposure inhibits fetal rat lung fibroblast lipid uptake and release. *Exp Lung Res* 2001;27:13–24. [PubMed: 11202061]
87. Torday JS. Dihydrotestosterone inhibits fibroblast-pneumonocyte factor-mediated synthesis of saturated phosphatidylcholine by fetal rat lung cells. *Biochim Biophys Acta* 1985;835:23–28. [PubMed: 4005273]
88. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. Testosterone inhibits adipogenic differentiation in 3T3–L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. *Endocrinology* 2006;147:141–154. [PubMed: 16210377]
89. Wang Y, Sakurai R, Cerny L, Torday JS, Rehan VK. Peroxisome Proliferator-Activated Receptor (PPAR) γ agonist enhance lung maturation in a neonatal rat model. *Pediatric Res* 2009;65:150–155.

Molecular Model of Alveolar Homeostasis and Disease

Fig. 1.

Coordinating effects of stretch on alveolar type II (ATII) cell expression of PTHrP and prostaglandin E₂ (PGE₂) (step 1), the expression of LIF PTHrP receptor (step 2), its downstream target LIF ADRP (step 3) and triglyceride uptake (step 4), and the interaction between LIF-produced leptin (step 5) and the ATII cell leptin receptor (step 6), which stimulates de novo surfactant phospholipid synthesis by ATII cells (step 7). We have also reported that stretching ATII cells in culture increases the production of PTHrP and leptin [1]. The effects of PTHrP and leptin are mutually exclusive, i.e., independent and unidirectional, since LIFs express the PTHrP receptor and leptin, but fetal ATII cells do not, although it should be noted that adult ATII cells do; conversely, ATII cells express PTHrP and the leptin receptor, but fibroblasts do not. Although it is difficult to compare the independent quantitative effects of stretch on PTHrP and leptin with their integrated effects on de novo surfactant phospholipid synthesis, the fold increase in each approximates the combined effect. Exposure to conditions such as hyperoxia, infection, nicotine, and/or fetal nutrient restriction can have molecular effects on the epithelial (step 8) and mesenchymal (step 9) cells

Table 1

Adverse effects of cigarette smoking during pregnancy on offspring pulmonary structure and function

1	Hypoplastic lungs with fewer air saccules [39–41]
2	Increased predisposition to both upper and lower respiratory tract infections [44–46]
3	Altered respiratory control and increased predisposition to sudden infant death syndrome [47,48]
4	Persistently reduced pulmonary function [42,43,49,50,75]
5	Increased incidence and severity of pediatric asthma [51,52]
6	Increased incidence of adult asthma and chronic obstructive pulmonary disease [53–55]

Table 2

Specific cellular and molecular effects of nicotine on the developing lung

Specific cellular/molecular effect	Proposed intervention (PPAR γ agonist $\pm$ Wnt antagonist)
<i>Alveolar type II cell</i> [4,61,74]	
Altered structure and increased proliferation	Normalized proliferation
Increased differentiation	Normalized differentiation
<i>Increased surfactant synthesis</i>	
Altered glucose and lipid metabolism	Normalized glucose and lipid metabolism
<i>Alveolar interstitial fibroblast</i> [3,5]	
Decreased lipofibroblast differentiation	Increased lipofibroblast differentiation
Increased myofibroblast differentiation	Decreased myofibroblast differentiation
<i>Epithelial-mesenchymal cross-talk</i> [3–5]	
Decreased PTHrP/PPAR γ signaling	Increased PTHrP/PPAR γ signaling
Increased Wnt signaling	Decreased Wnt signaling